Important News from CymaBay Therapeutics
Primary Biliary Cholangitis
Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that results from the ENHANCE phase 3 global study evaluating seladelpar for Primary Biliary Cholangitis (PBC) have been published in Hepatology. The authors . . .
This content is for paid subscribers.
Today’s Highlights April 21, 2023